Find Fingolimod Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 162359-56-0, Fty720, Fingolimod hcl, Gilenia, Gilenya, Fty 720
Molecular Formula
C19H34ClNO2
Molecular Weight
343.9  g/mol
InChI Key
SWZTYAVBMYWFGS-UHFFFAOYSA-N
FDA UNII
G926EC510T

Fingolimod Hydrochloride
A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.
1 2D Structure

Fingolimod Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride
2.1.2 InChI
InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
2.1.3 InChI Key
SWZTYAVBMYWFGS-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
2.2 Other Identifiers
2.2.1 UNII
G926EC510T
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol Hydrochloride

2. Fingolimod

3. Fty 720

4. Fty-720

5. Fty720

6. Gilenia

7. Gilenya

2.3.2 Depositor-Supplied Synonyms

1. 162359-56-0

2. Fty720

3. Fingolimod Hcl

4. Gilenia

5. Gilenya

6. Fty 720

7. Fty-720

8. Fingolimod (hydrochloride)

9. Fingolimod (fty720) Hcl

10. 2-amino-2-(4-octylphenethyl)propane-1,3-diol Hydrochloride

11. Fingolimod, Hcl

12. Fty720 Hydrochloride

13. Fingolimod Hydrochloride [usan]

14. 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol Hydrochloride

15. Fty720 Free Base

16. Chebi:63112

17. Fingolimod Hydrochlorid

18. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride

19. Fingolimod (as Hydrochloride)

20. Fty-720 Hydrochloride

21. 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Hydrochloride

22. G926ec510t

23. Mfcd00939512

24. 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol Hydrochloride

25. Gilenya (tn)

26. 1,3-propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, Hydrochloride

27. 1,3-propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, Hydrochloride

28. 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, Hydrochloride

29. Fty-720a

30. Fingolimod (fty720)

31. Imusera

32. Unii-g926ec510t

33. 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol Hydrochloride

34. Fty720,fingolimod

35. Fingolimodhydrochloride

36. Fin;limod Hydrochloride

37. Fty720 - Fingolimod

38. Fingolimod Hclfty-720

39. Epitope Id:156573

40. Schembl81362

41. Mls006010179

42. Chembl544665

43. Fingolimod Hydrochloride- Bio-x

44. Dtxsid00167364

45. Ex-a960

46. Tdi-132

47. Bcpp000225

48. Bcp01808

49. 2-amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol Hcl

50. Fingolimod Hydrochloride (jan/usan)

51. Fingolimod Hydrochloride [mi]

52. S5002

53. Fingolimod Hydrochloride [jan]

54. Akos005145784

55. Ac-1929

56. Am84549

57. Bcp9000705

58. Ccg-265016

59. Cs-0114

60. Ks-1172

61. Fingolimod Hydrochloride [usp-rs]

62. Fingolimod Hydrochloride [who-dd]

63. Bf164458

64. Hy-12005

65. Smr004701287

66. Sy057854

67. Db-014816

68. A8548

69. F1018

70. Ft-0643569

71. Sw219384-1

72. Ec-000.2314

73. Fingolimod Hydrochloride [orange Book]

74. A25158

75. D04187

76. Fingolimod Hydrochloride [ep Monograph]

77. Fingolimod Hydrochloride [usp Monograph]

78. 359f560

79. Sr-01000942237

80. Q-101363

81. Sr-01000942237-2

82. Q27132395

83. 2-(4-octylphenethyl)-2-aminopropane-1,3-diol Hydrochloride

84. 2-amino-2-[2-(4-octylphenyl) Ethyl]-1,3-propanediol Hydrochloride

85. 2-amino-2-[2-(4-octylphenyl)-ethyl]-1,3-propanediol Hydrochloride

86. [1-hydroxy-2-(hydroxymethyl)-4-(4-octylphenyl)butan-2-yl]azanium;chloride

87. 2-amino-2-[2-(4-n-octylphenyl)ethyl]propane-1,3-diol Hydrochloride

88. 2-amino-2-[2-(4-octyl-phenyl)-ethyl]-propane -1,3-diol Hydrochloride

89. 2-amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol Hydrochloride

90. 1,3-propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-, Hydrochloride (1:1)

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 343.9 g/mol
Molecular Formula C19H34ClNO2
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count3
Rotatable Bond Count12
Exact Mass343.2278070 g/mol
Monoisotopic Mass343.2278070 g/mol
Topological Polar Surface Area66.5 Ų
Heavy Atom Count23
Formal Charge0
Complexity258
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameGilenya
PubMed HealthFingolimod (By mouth)
Drug ClassesImmune Modulator
Drug LabelFingolimod is a sphingosine 1-phosphate receptor modulator.Chemically, fingolimod is 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride. Its structure is shown below: Fingolimod hydrochloride is a white to practically white powder that i...
Active IngredientFingolimod
Dosage FormCapsule
RouteOral
Strength0.5mg
Market StatusPrescription
CompanyNovartis

2 of 2  
Drug NameGilenya
PubMed HealthFingolimod (By mouth)
Drug ClassesImmune Modulator
Drug LabelFingolimod is a sphingosine 1-phosphate receptor modulator.Chemically, fingolimod is 2-amino-2-[2-(4-octylphenyl)ethyl]propan-1,3-diol hydrochloride. Its structure is shown below: Fingolimod hydrochloride is a white to practically white powder that i...
Active IngredientFingolimod
Dosage FormCapsule
RouteOral
Strength0.5mg
Market StatusPrescription
CompanyNovartis

4.2 Drug Indication

Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:

- Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 and 5. 1).

or

- Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Sphingosine 1 Phosphate Receptor Modulators

Agents that affect the function of G-protein coupled SPHINGOSINE 1-PHOSPHATE RECEPTORS. Their binding to the receptors blocks lymphocyte migration and are often used as IMMUNOSUPPRESSANTS. (See all compounds classified as Sphingosine 1 Phosphate Receptor Modulators.)


Immunosuppressive Agents

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Sphingosine 1-phosphate Receptor Modulator [EPC]; Sphingosine 1-Phosphate Receptor Modulators [MoA]
5.3 ATC Code

L04AA27


API SUPPLIERS

read-more
read-more

01

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

02

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Metrochem

03

Synnat Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSynnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Synnat

04

HRV Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
HRV Global Life Sciences

05

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
TAPI Company Banner

06

Honour Lab Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS arrow-down JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
Company Banner

07

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

08

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

09

Novugen

U.A.E

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

Novugen

U.A.E

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

HEC Pharm

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

RDD
Not Confirmed
arrow

HEC Pharm

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
RDD
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

Fingolimod Hydrochloride IH

Date of Issue : 2025-09-03

Valid Till : 2028-09-02

Written Confirmation Number : WC-0362

Address of the Firm : Plot No:4, Hetero Infrastructure SEZ Ltd.,Narasapuram, Visakhapatnam-531081, And...

Company Banner

02

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride IH/Ph. Eur

Date of Issue : 2025-08-22

Valid Till : 2028-08-21

Written Confirmation Number : WC-0082

Address of the Firm : Karakhadi, Plot No. 842-843, At - Karakhdi, Tal. - Padra, Dist -Vadodara, Gujara...

blank

03

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride IH

Date of Issue : 2022-07-06

Valid Till : 2025-06-25

Written Confirmation Number : WC-0057n

Address of the Firm : Plot No. 3109, GIDC, Industrial Estate Ankleshwar, Distt- Bharuch - 393002, Guja...

blank

04

Biocon

India
RDD
Not Confirmed
arrow

Biocon

India
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride IH

Date of Issue : 2025-08-19

Valid Till : 2028-07-02

Written Confirmation Number : WC-0100

Address of the Firm : Special Economic Zone, Plot No. 2, 3, 4 & 5, Phase IV, Bommasandra-Jigani Link R...

blank

05

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride EP

Date of Issue : 2025-09-26

Valid Till : 2028-07-02

Written Confirmation Number : WC-0226

Address of the Firm : D-24 & D-24/1, M.I.D.C., Kurkumbh, Taluka: Daund, District. Pune -413802, Mahara...

blank

06

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Fingolimod hydrochlorid IH/EP

Date of Issue : 2025-09-19

Valid Till : 2028-05-05

Written Confirmation Number : WC-0349

Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

blank

07

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Fingolimod IH

Date of Issue : 2025-09-19

Valid Till : 2028-05-05

Written Confirmation Number : WC-0349

Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

blank

08

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride IH

Date of Issue : 2026-01-01

Valid Till : 2028-07-02

Written Confirmation Number : WC-0147

Address of the Firm : 100% EOU, Plot No.33, 33A, 40 to 47,Block C, D, E, H, I& AM,Raichur Industrial G...

blank

09

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride USP/EP

Date of Issue : 2023-03-21

Valid Till : 2026-03-20

Written Confirmation Number : WC-0552

Address of the Firm : Plot No. D-2/CH/41A, GIDC Industrial Estate, Dahej Il, Bharuch-392140, Gujarat, ...

blank

10

RDD
Not Confirmed
arrow
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride USP/Ph.Eur

Date of Issue : 2022-06-07

Valid Till : 2025-07-02

Written Confirmation Number : WC-0157

Address of the Firm : Plot No. 1-A/2 & Plot No. 1-A/3, M.I.D.C. Taloja Industrial Area, Taloja - 41020...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Fingolimod HCl, a miscellaneous product targeting Sphingosine 1-phosphate receptor (S1P1), shows promise in treating multiple sclerosis.


Lead Product(s): Fingolimod Hydrochloride,Inapplicable

Therapeutic Area: Neurology Brand Name: Gilenya-Generic

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 27, 2026

blank

01

RDD
Not Confirmed
RDD
Not Confirmed

Details : Fingolimod HCl, a miscellaneous product targeting Sphingosine 1-phosphate receptor (S1P1), shows promise in treating multiple sclerosis.

Product Name : Gilenya-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 27, 2026

blank

Details:

Vumerity (Diroximel Fumarate) is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of multiple sclerosis.


Lead Product(s): Diroximel fumarate,Fingolimod Hydrochloride,Dimethyl Fumarate

Therapeutic Area: Neurology Brand Name: Vumerity

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 19, 2026

blank

02

Biogen

U.S.A
arrow
RDD
Not Confirmed

Biogen

U.S.A
arrow
RDD
Not Confirmed

Details : Vumerity (Diroximel Fumarate) is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of multiple sclerosis.

Product Name : Vumerity

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 19, 2026

blank

Details:

Ublituximab is a antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.


Lead Product(s): Ublituximab,Fingolimod Hydrochloride

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 23, 2025

blank

03

RDD
Not Confirmed
RDD
Not Confirmed

Details : Ublituximab is a antibody drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

October 23, 2025

blank

Details:

Tascenso (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.


Lead Product(s): Fingolimod Hydrochloride,Inapplicable

Therapeutic Area: Neurology Brand Name: Tascenso

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 13, 2023

blank

04

Cycle Pharmaceuticals

United Kingdom
arrow
RDD
Not Confirmed

Cycle Pharmaceuticals

United Kingdom
arrow
RDD
Not Confirmed

Details : Tascenso (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 yea...

Product Name : Tascenso

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 13, 2023

blank

Details:

Tascenso (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.


Lead Product(s): Fingolimod Hydrochloride,Inapplicable

Therapeutic Area: Neurology Brand Name: Tascenso

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 17, 2023

blank

05

Cycle Pharmaceuticals

United Kingdom
arrow
RDD
Not Confirmed

Cycle Pharmaceuticals

United Kingdom
arrow
RDD
Not Confirmed

Details : Tascenso (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 yea...

Product Name : Tascenso

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 17, 2023

blank

Details:

Fingolimod, an orally available immunomodulatory drug, is a sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS).


Lead Product(s): Fingolimod Hydrochloride,Inapplicable

Therapeutic Area: Neurology Brand Name: Gilenya-Generic

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 31, 2022

blank

06

RDD
Not Confirmed
RDD
Not Confirmed

Details : Fingolimod, an orally available immunomodulatory drug, is a sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS).

Product Name : Gilenya-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 31, 2022

blank

Details:

GILENYA (fingolimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and children 10 years of age and older.


Lead Product(s): Fingolimod Hydrochloride,Inapplicable

Therapeutic Area: Neurology Brand Name: Gilenya

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 21, 2022

blank

07

RDD
Not Confirmed
RDD
Not Confirmed

Details : GILENYA (fingolimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and children 10 years of a...

Product Name : Gilenya

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 21, 2022

blank

Details:

Mean reduction in ADSI score from baseline was -4.05 (-60.62% mean reduction) for FMX114 (tofacitinib) treated lesions compared to -3.48 (-51.32% mean reduction) for vehicle treated lesions at week 4 (p=0.228, OC, ITT).


Lead Product(s): Tofacitinib Citrate,Fingolimod Hydrochloride

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 10, 2022

blank

08

RDD
Not Confirmed
RDD
Not Confirmed

Details : Mean reduction in ADSI score from baseline was -4.05 (-60.62% mean reduction) for FMX114 (tofacitinib) treated lesions compared to -3.48 (-51.32% mean reduction) for vehicle treated lesions at week 4 (p=0.228, OC, ITT).

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 10, 2022

blank

Details:

Gilenya® (fingolimod), an oral, once-daily at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).


Lead Product(s): Fingolimod Hydrochloride,Inapplicable

Therapeutic Area: Neurology Brand Name: Gilenya

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 21, 2022

blank

09

RDD
Not Confirmed
RDD
Not Confirmed

Details : Gilenya® (fingolimod), an oral, once-daily at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).

Product Name : Gilenya

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 21, 2022

blank

Details:

FMX114 (tofacitinib), is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod, which has been designed to address both the source and cause of inflammation in AD.


Lead Product(s): Tofacitinib Citrate,Fingolimod Hydrochloride

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 17, 2022

blank

10

RDD
Not Confirmed
RDD
Not Confirmed

Details : FMX114 (tofacitinib), is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod, which has been designed to address both the source and cause of inflammation in AD.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 17, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

RDD
Not Confirmed
arrow
RDD
Not Confirmed
arrow

CAS Number : 2189-60-8

End Use API : Fingolimod Hydrochloride

About The Company : Established in Gujarat (India), we, Niranjan Chemicals have grown into a well-established manufacturer and supplier of Drugs Intermediates. Each passing year, w...

blank

02

RDD
Not Confirmed
arrow
RDD
Not Confirmed
arrow

CAS Number : 111-64-8

End Use API : Fingolimod Hydrochloride

About The Company : Novaphene comprises of two business divisions, Manufacturing - Novaphene Specialities Pvt. Ltd. and Distribution - Novaphene Impex. We are privately managed and...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Direct Compression

read-more
read-more

Lubricants & Glidants

read-more
read-more

Empty Capsules

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Parenteral

read-more
read-more

Granulation

read-more
read-more

Coating Systems & Additives

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Emulsifying Agents

read-more
read-more

Solubilizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

Brand Name : Fingolimod

United Kingdom
arrow
RDD
Not Confirmed

Brand Name : Fingolimod

United Kingdom
arrow
RDD
Not Confirmed

Company : Accord Healthca

Fingolimod HCl

Drug Cost (USD) : 8,647,579

Year : 2023

Prescribers : 627

Prescriptions : 3974

blank

02

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Apotex Corp

Fingolimod HCl

Drug Cost (USD) : 7,142,410

Year : 2023

Prescribers : 289

Prescriptions : 1302

blank

03

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Ascend Laborato

Fingolimod HCl

Drug Cost (USD) : 360,416

Year : 2023

Prescribers : 24

Prescriptions : 63

blank

04

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Camber Pharmace

Fingolimod HCl

Drug Cost (USD) : 4,280,896

Year : 2023

Prescribers : 194

Prescriptions : 906

blank

05

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Dr.Reddy'S Lab

Fingolimod HCl

Drug Cost (USD) : 26,336,173

Year : 2023

Prescribers : 683

Prescriptions : 4620

blank

06

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Glenmark Pharma

Fingolimod HCl

Drug Cost (USD) : 2,232,447

Year : 2023

Prescribers : 114

Prescriptions : 598

blank

07

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Mylan

Fingolimod HCl

Drug Cost (USD) : 38,514,769

Year : 2023

Prescribers : 1352

Prescriptions : 7440

blank

08

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Rising Pharm

Fingolimod HCl

Drug Cost (USD) : 13,732,229

Year : 2023

Prescribers : 634

Prescriptions : 2887

blank

09

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Sun Pharmaceuti

Fingolimod HCl

Drug Cost (USD) : 942,007

Year : 2023

Prescribers : 45

Prescriptions : 174

blank

10

arrow
RDD
Not Confirmed
arrow
RDD
Not Confirmed

Company : Zydus Pharmaceu

Fingolimod HCl

Drug Cost (USD) : 6,828,525

Year : 2023

Prescribers : 239

Prescriptions : 1268

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Gilenya

Fingolimod

arrow
RDD
Not Confirmed

Brand Name : Gilenya

Switzerland
arrow
RDD
Not Confirmed

Fingolimod

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 3,003

2019 Revenue in Millions : 3,223

Growth (%) : -7

blank

02

Brand Name : Royalty from Gilenya

Fingolimod

arrow
RDD
Not Confirmed

Brand Name : Royalty from Gilenya

Japan
arrow
RDD
Not Confirmed

Fingolimod

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 40

2019 Revenue in Millions : 88

Growth (%) : -55

blank

03

Brand Name : Imusera

Fingolimod Hydrochloride

arrow
RDD
Not Confirmed

Brand Name : Imusera

Japan
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride

Main Therapeutic Indication : Neurology

Currency : USD

2020 Revenue in Millions : 38

2019 Revenue in Millions : 0

Growth (%) : 100

blank

04

Brand Name : Gilenya

Fingolimod

arrow
RDD
Not Confirmed

Brand Name : Gilenya

Switzerland
arrow
RDD
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 2,787

2020 Revenue in Millions : 3,003

Growth (%) : -7

blank

05

Brand Name : Imusera

Fingolimod Hydrochloride

arrow
RDD
Not Confirmed

Brand Name : Imusera

Japan
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 33

2020 Revenue in Millions : 37

Growth (%) : -5

blank

06

Brand Name : Royalty from Gilenya

Fingolimod

arrow
RDD
Not Confirmed

Brand Name : Royalty from Gilenya

Japan
arrow
RDD
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 35

2020 Revenue in Millions : 39

Growth (%) : -2

blank

07

Brand Name : Gilenya

Fingolimod

arrow
RDD
Not Confirmed

Brand Name : Gilenya

Switzerland
arrow
RDD
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 2,013

2021 Revenue in Millions : 2,787

Growth (%) : -28

blank

08

Brand Name : Royalty from Gilenya

Fingolimod

arrow
RDD
Not Confirmed

Brand Name : Royalty from Gilenya

Japan
arrow
RDD
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 971

2021 Revenue in Millions : 30

Growth (%) : 3,097

blank

09

Brand Name : Imusera

Fingolimod Hydrochloride

arrow
RDD
Not Confirmed

Brand Name : Imusera

Japan
arrow
RDD
Not Confirmed

Fingolimod Hydrochloride

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 7

2021 Revenue in Millions : 32

Growth (%) : -79

blank

10

Brand Name : Gilenya

Fingolimod

arrow
RDD
Not Confirmed

Brand Name : Gilenya

Switzerland
arrow
RDD
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 925

2022 Revenue in Millions : 2,013

Growth (%) : -54

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 162359-56-0 / Fingolimod Hydrochloride API manufacturers, exporters & distributors?

Fingolimod Hydrochloride manufacturers, exporters & distributors 1

79

PharmaCompass offers a list of Fingolimod Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fingolimod Hydrochloride manufacturer or Fingolimod Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fingolimod Hydrochloride manufacturer or Fingolimod Hydrochloride supplier.

API | Excipient name

Fingolimod Hydrochloride

Synonyms

162359-56-0, Fty720, Fingolimod hcl, Gilenia, Gilenya, Fty 720

Cas Number

162359-56-0

Unique Ingredient Identifier (UNII)

G926EC510T

About Fingolimod Hydrochloride

A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.

FTY720,Fingolimod Manufacturers

A FTY720,Fingolimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of FTY720,Fingolimod, including repackagers and relabelers. The FDA regulates FTY720,Fingolimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. FTY720,Fingolimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of FTY720,Fingolimod manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

FTY720,Fingolimod Suppliers

A FTY720,Fingolimod supplier is an individual or a company that provides FTY720,Fingolimod active pharmaceutical ingredient (API) or FTY720,Fingolimod finished formulations upon request. The FTY720,Fingolimod suppliers may include FTY720,Fingolimod API manufacturers, exporters, distributors and traders.

click here to find a list of FTY720,Fingolimod suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

FTY720,Fingolimod USDMF

A FTY720,Fingolimod DMF (Drug Master File) is a document detailing the whole manufacturing process of FTY720,Fingolimod active pharmaceutical ingredient (API) in detail. Different forms of FTY720,Fingolimod DMFs exist exist since differing nations have different regulations, such as FTY720,Fingolimod USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A FTY720,Fingolimod DMF submitted to regulatory agencies in the US is known as a USDMF. FTY720,Fingolimod USDMF includes data on FTY720,Fingolimod's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The FTY720,Fingolimod USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of FTY720,Fingolimod suppliers with USDMF on PharmaCompass.

FTY720,Fingolimod JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The FTY720,Fingolimod Drug Master File in Japan (FTY720,Fingolimod JDMF) empowers FTY720,Fingolimod API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the FTY720,Fingolimod JDMF during the approval evaluation for pharmaceutical products. At the time of FTY720,Fingolimod JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of FTY720,Fingolimod suppliers with JDMF on PharmaCompass.

FTY720,Fingolimod CEP

A FTY720,Fingolimod CEP of the European Pharmacopoeia monograph is often referred to as a FTY720,Fingolimod Certificate of Suitability (COS). The purpose of a FTY720,Fingolimod CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of FTY720,Fingolimod EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of FTY720,Fingolimod to their clients by showing that a FTY720,Fingolimod CEP has been issued for it. The manufacturer submits a FTY720,Fingolimod CEP (COS) as part of the market authorization procedure, and it takes on the role of a FTY720,Fingolimod CEP holder for the record. Additionally, the data presented in the FTY720,Fingolimod CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the FTY720,Fingolimod DMF.

A FTY720,Fingolimod CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. FTY720,Fingolimod CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of FTY720,Fingolimod suppliers with CEP (COS) on PharmaCompass.

FTY720,Fingolimod WC

A FTY720,Fingolimod written confirmation (FTY720,Fingolimod WC) is an official document issued by a regulatory agency to a FTY720,Fingolimod manufacturer, verifying that the manufacturing facility of a FTY720,Fingolimod active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting FTY720,Fingolimod APIs or FTY720,Fingolimod finished pharmaceutical products to another nation, regulatory agencies frequently require a FTY720,Fingolimod WC (written confirmation) as part of the regulatory process.

click here to find a list of FTY720,Fingolimod suppliers with Written Confirmation (WC) on PharmaCompass.

FTY720,Fingolimod NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing FTY720,Fingolimod as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for FTY720,Fingolimod API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture FTY720,Fingolimod as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain FTY720,Fingolimod and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a FTY720,Fingolimod NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of FTY720,Fingolimod suppliers with NDC on PharmaCompass.

FTY720,Fingolimod GMP

FTY720,Fingolimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of FTY720,Fingolimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right FTY720,Fingolimod GMP manufacturer or FTY720,Fingolimod GMP API supplier for your needs.

FTY720,Fingolimod CoA

A FTY720,Fingolimod CoA (Certificate of Analysis) is a formal document that attests to FTY720,Fingolimod's compliance with FTY720,Fingolimod specifications and serves as a tool for batch-level quality control.

FTY720,Fingolimod CoA mostly includes findings from lab analyses of a specific batch. For each FTY720,Fingolimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

FTY720,Fingolimod may be tested according to a variety of international standards, such as European Pharmacopoeia (FTY720,Fingolimod EP), FTY720,Fingolimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (FTY720,Fingolimod USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty